Post-market use of teduglutide (TED) in a large cohort of adults with short bowel syndrome (SBS)

Rationale: TED, a GLP-2 analogue, is available in France since 2015 for the treatment of SBS patients with chronic intestinal failure CIF (SBS-CIF). The cost of this drug is high and there is few data about the potential candidates in real life. The aim of the study was to analyze in a real-life setting the implementation of TED in a cohort of SBS-CIF patients as well as the treatment outcomes.

Source: Clinical Nutrition ESPEN - December 1, 2023 Category: Nutrition Authors: B. De Dreuille, A. Nuzzo, J. Bataille, C. Mailhat, L. Billiauws, F. Joly Source Type: research